The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Bispecific Gamma Delta-T-Cell Engager Directed to EGFR

Geo Regions

Bispecific Gamma Delta-T-Cell Engager Directed to EGFR

PF-08046053, SGN-EGFRd2 is an investigational compound. Its safety and efficacy have not been established.

Overview + Rationale

  • EGFR is a cell surface receptor expressed in many cancer types.1 
  • γ9δ2-T cells are a conserved T cell subset that can induce cell death in a wide range of malignancies.2 
  • Activated γ9δ2-T cells directly induce cell lysis as well as activate downstream innate and adaptive immune cells, enhancing tumor cell killing.3-5 
  • SGN-EGFRd2 is a novel, investigational bispecific gamma delta (γδ)-T cell engager directed to EGFR, comprising a bispecific humanized heavy chain-only antibody designed to conditionally activate γ9δ2-T cells by simultaneously binding EGFR and γ9δ2 TCR.6 
  • Full activation of γ9δ2-T cells and tumor-directed cytotoxicity requires the presence of pAg, a stress signal found in malignant cells, but not in healthy cells.6,7 
  • SGN-EGFRd2 is under investigation in advanced solid tumors.8

Mechanism of Action

Stage of Development

Proposed Mechanism of Action for a Bispecific Gamma Delta 9y6)-T-Cell Engager Directed to EGFR*
Advanced Solid Tumors
Phase 1 Monotherapy

References: 1. Thomas R. Front Oncol. 2019: 800. 2. Melandri D. Nat Immunol. 2018: 1352-65. 3. Devilder MC. J Immunol. 2006: 1386-96. 4. Vantourout P. Nat Rev Immunol. 2013: 88-100. 5. Brandes M. Science. 2005: 264-8. 6. King LA. Cancer Immunol Res. 2023: 1237- 52. 7. Yuan L. Nature. 2023: 840-8. 8. Clinicaltrials.gov. NCT05983133. Available at: https://clinicaltrials.gov/study/NCT05983133. Accessed January 4, 2024.